Dostinex Related Published Studies
Well-designed clinical trials related to Dostinex (Cabergoline)
Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. [2010.11]
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study. [2010.06]
A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. [2010.05]
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. [2007.08]
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. [2007.04.15]
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. [2007.02.01]
Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. [2006.11]
Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). [2006.09.26]
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). [2005.03]
Effective cabergoline treatment in idiopathic restless legs syndrome. [2004.12.28]
Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer. [2004.11]
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia. [2004.07]
[Cabergoline for inhibition of lactation] [2004.01]
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. [2004]
Evaluation of cabergoline and buserelin efficacy for oestrous induction in the bitch. [2003.12]
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. [2003]
Control of fertility in the red fox (Vulpes vulpes): effect of a single oral dose of cabergoline in early pregnancy. [2002]
Effectiveness of cabergoline for termination of pregnancy in silver fox (Vulpes vulpes fulva). [2001.10]
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. [2001.09]
Control of red fox (Vulpes vulpes) fertility with cabergoline: dose response and timing of intervention. [2001.07]
Clinical data on restless legs syndrome: a dose-finding study with cabergoline. [2001]
A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. [2000.07]
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. [2000.04]
Effect of chronic administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome. [1999.02]
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. [1998.03]
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. [1998]
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. [1997.02]
[Treatment of hyperprolactinemic amenorrhea with cabergoline] [1997]
The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. [1996.10]
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. [1996.09]
The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. [1996.07]
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. [1996.04]
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. [1996.01]
[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study] [1995.04.29]
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. [1994.12]
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. [1994.10.06]
Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. [1994.10]
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. [1994.01]
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. [1993.10]
Controlled study of the antiparkinsonian activity and tolerability of cabergoline. [1993.03]
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. [1992.12]
Oral cabergoline. Single-dose inhibition of puerperal lactation. [1991.10]
Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery. [1991]
Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. [1988.11]
Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline. [1988.03]
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. [1988.01]
Well-designed clinical trials possibly related to Dostinex (Cabergoline)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. [2011.10]
Neuromodulatory neurotransmitters influence LTP-like plasticity in human cortex: a pharmaco-TMS study. [2011.08]
The intravaginal application of misoprostol improves induction of abortion with aglepristone. [2011.07.01]
Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? [2011.05]
Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. [2010.02]
Tolerability and safety of ropinirole versus other dopamine agonists and levodopa
in the treatment of Parkinson's disease: meta-analysis of randomized controlled
trials. [2010]
Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. [2009.12]
Augmentation in restless legs syndrome is associated with low ferritin. [2008.07]
Repeated induction of abortion in bitches and the effect on plasma concentrations of relaxin, progesterone and estradiol-17beta. [2007.10.01]
Modification of practice-dependent plasticity in human motor cortex by neuromodulators. [2006.08]
Clinical inquiries. What is the recommended evaluation and treatment for elevated serum prolactin? [2005.10]
Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. [2005.03]
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches. [2001.05.31]
Other research related to Dostinex (Cabergoline)
Cabergoline plus metformin therapy effects on menstrual irregularity and androgen
system in polycystic ovary syndrome women with hyperprolactinemia. [2015]
Combination therapy for Cushing's disease: effectiveness of two schedules of
treatment: should we start with cabergoline or ketoconazole? [2014]
Does cabergoline help in decreasing endometrioma size compared to LHRH agonist? A
prospective randomized study. [2014]
Clinical outcome according to timing of cabergoline initiation for prevention of
OHSS: a randomized controlled trial. [2013]
Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent
failure. [2012]
Cabergoline for preventing ovarian hyperstimulation syndrome. [2012]
Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on
body weight and glucose tolerance in obese adults. [2012]
Randomized Pilot Study of Cabergoline, a Dopamine Receptor Agonist: Effects on Body Weight and Glucose Tolerance in Obese Adults. [2011.11.10]
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. [2011.09]
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. [2011.06]
Place of cabergoline in acromegaly: a meta-analysis. [2011.05]
Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. [2011.05]
Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline. [2011.02]
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a
systematic review of randomized controlled trials and meta-analysis. [2011]
Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. [2010.12]
Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. [2010.11]
Cabergoline monotherapy in the long-term treatment of Cushing's disease. [2010.11]
Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. [2010.11]
Resolution of third nerve palsy following treatment of prolactinoma with cabergoline. [2010.10]
The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. [2010.10]
Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. [2010.09]
Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review. [2010.09]
Cabergoline monotherapy in the long-term treatment of Cushing's disease. [2010.08.11]
Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. [2010.08]
Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. [2010.08]
Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. [2010.07]
Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. [2010.06.23]
Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. [2010.06]
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. [2010.06]
Intravaginal application of misoprostol improves pregnancy termination with cabergoline and alfaprostol in dogs. [2010.05]
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. [2010.05]
Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. [2010.04]
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. [2010.04]
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? [2010.01]
Medical treatment in Cushing's syndrome: dopamine agonists and cabergoline. [2010]
Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. [2010]
Effectiveness of short-term maintenance treatment with cabergoline in
microadenoma-related and idiopathic hyperprolactinemia. [2010]
A comparison of bromocriptine & cabergoline on fertility outcome of
hyperprolactinemic infertile women undergoing intrauterine insemination. [2010]
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual
mastalgia: a randomised, open-label study. [2010]
[Cabergoline in hyperprolactinemia and valvular heart disease] [2009.10]
Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. [2009.10]
High dose cabergoline in management of ovarian hyperstimulation syndrome. [2009.09]
|
